FDA Brief

Warning letters Drugs

FDA warning letter to

Cosmetic Manufacturers Pty Ltd.

High riskIssued Feb 6Posted Feb 17Center for Drug Evaluation and Research (CDER)

FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

What happened

FDA inspected the drug manufacturing facility from March 31 to April 8, 2025, and found significant CGMP violations for finished pharmaceuticals. The agency cited inadequate batch release testing, insufficient laboratory controls and specifications, inadequate process validation and environmental controls, and unsuitable equipment qualification and cleaning validation. FDA also said all drugs from the firm were placed on Import Alert 66-40 on January 8, 2026.

What FDA found

  1. The firm released drug batches without testing every batch for all critical quality attributes, including active ingredient identity and strength, particulates and foreign matter, and preservative content.

    21 CFR 211.165(a)
  2. The firm's laboratory controls and specifications were inadequate for a component used in products and equipment cleaning, including incomplete testing and unproven test methods.

    21 CFR 211.160(b)
  3. The firm's process validation and environmental controls were inadequate, including unjustified sampling, a failed validation criterion that was accepted, and inadequate microbial controls for filling areas.

    21 CFR 211.100(a)
  4. The firm had not shown its filling equipment and cleaning procedures were suitable, including inadequate qualification of a filler machine and cleaning validation that did not show reproducibility.

    21 CFR 211.63

What FDA wants

FDA tells the firm to respond in writing within 15 working days with corrective actions and steps to prevent recurrence, and to notify FDA before resuming U.S.-regulated drug manufacturing. FDA may re-inspect and may withhold approval or refuse admission until the violations are corrected.

Who should pay attention

  • contract customers and product owners that use this site
  • U.S. distributors and importers of its drug products
  • quality teams at contract manufacturers making drugs for the U.S. market

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk